Identification and characterization of a core fucosidase from the bacterium .

J Biol Chem

From the Department of Medical Microbiology, Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai 200032 and

Published: January 2018

All reported α-l-fucosidases catalyze the removal of nonreducing terminal l-fucoses from oligosaccharides or their conjugates, while having no capacity to hydrolyze core fucoses in glycoproteins directly. Here, we identified an α-fucosidase from the bacterium with catalytic activity against core α-1,3-fucosylated substrates, and we named it core fucosidase I (cFase I). Using site-specific mutational analysis, we found that three acidic residues (Asp-242, Glu-302, and Glu-315) in the predicted active pocket are critical for cFase I activity, with Asp-242 and Glu-315 acting as a pair of classic nucleophile and acid/base residues and Glu-302 acting in an as yet undefined role. These findings suggest a catalytic mechanism for cFase I that is different from known α-fucosidase catalytic models. In summary, cFase I exhibits glycosidase activity that removes core α-1,3-fucoses from substrates, suggesting cFase I as a new tool for glycobiology, especially for studies of proteins with core fucosylation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787802PMC
http://dx.doi.org/10.1074/jbc.M117.804252DOI Listing

Publication Analysis

Top Keywords

core fucosidase
8
core
6
cfase
5
identification characterization
4
characterization core
4
fucosidase bacterium
4
bacterium reported
4
reported α-l-fucosidases
4
α-l-fucosidases catalyze
4
catalyze removal
4

Similar Publications

Symbiotic interactions between humans and our communities of resident gut microbes (microbiota) play many roles in health and disease. Some gut bacteria utilize mucus as a nutrient source and can under certain conditions damage the protective barrier it forms, increasing disease susceptibility. We investigated how a known mucin degrader that has been implicated in inflammatory bowel diseases (IBDs)-degrades mucin glycoproteins or their component -linked glycans to understand its effects on the availability of mucin-derived nutrients for other bacteria.

View Article and Find Full Text PDF

A Robust α-l-Fucosidase from for Glycoengineering Therapeutic Antibodies.

ACS Chem Biol

July 2024

School of Pharmacy, College of Pharmacy, Taipei Medical University, No. 250 Wuxing Street, Taipei 11031, Taiwan.

Article Synopsis
  • Eliminating core fucose from Fc antibody glycoforms can increase the efficacy of therapeutic antibodies, particularly enhancing ADCC, but traditional fucosidases have limitations in effectiveness.
  • A newly identified α-l-fucosidase (fucA) from a bacterium shows high reactivity to specific fucose linkages while demonstrating robust stability and activity under various conditions.
  • Using fucA in glycoengineering of the antibody adalimumab achieved efficient removal of core fucose, leading to a more effective afucosylated form with improved binding to Fcγ receptor IIIa.
View Article and Find Full Text PDF

Among the first microorganisms to colonize the human gut of breastfed infants are bacteria capable of fermenting human milk oligosaccharides (HMOs). One of the most abundant HMOs, 2'-fucosyllactose (2'-FL), may specifically drive bacterial colonization of the intestine. Recently, differential growth has been observed across multiple species of on various HMOs including 2'-FL.

View Article and Find Full Text PDF

The mucolytic human gut microbiota specialist Akkermansia muciniphila is proposed to boost mucin-secretion by the host, thereby being a key player in mucus turnover. Mucin glycan utilization requires the removal of protective caps, notably fucose and sialic acid, but the enzymatic details of this process remain largely unknown. Here, we describe the specificities of ten A.

View Article and Find Full Text PDF

Enhanced antibody-defucosylation capability of α-L-fucosidase by proximity-based protein fusion.

Biochem Biophys Res Commun

February 2023

CAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai, 201203, PR China. Electronic address:

Up to date, the reported fucosidases generally show poor activities toward the IgG core-fucose, which limits the efficiency of ENGase-catalyzed glycoengineering process. However, EndoS or EndoS2 owns excellent activity and great selectivity towards the N-glycosylation of IgGs, and their non-catalytic domains are deduced to have specific interactions to IgG Fc domain that result in the great activity and selectivity. Herein, we constructed a series fusion protein of AlfC (an α-l-fucosidase from Lactobacillus casei BL23) with EndoS/S2 non-catalytic domain by replacing the catalytic GH (glycan hydrolase) domain of EndoS/S2 with the AlfC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!